Calls
1
u/justinrosser
Reddit r/biotech_stocks
Win Rate
0.0%
return
-2.5%
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Sep 13
$0.80
-2.5%
Author argues Invivyd's risk/reward is compelling ahead of late-Q3 Phase 3 top-line data for next-gen COVID antibody VYD2311 across the DECLARATION efficacy and LIBERTY side-effect comparison trials. Management upsized DECLARATION by ~500 patients, which the author reads as confidence in statistical power, and a favorable LIBERTY result versus mRNA shots could open a large market of vaccine-avoidant patients. IVVD already generates revenue from first-gen antibody PEMGARDA, and the Board Chair stepping into the CEO role suggests preparation for commercial execution or strategic positioning. A clean readout would position VYD2311 for a BLA filing and, given the low valuation and micro-cap dynamics, could trigger a rapid re-rate toward analyst price targets.
Pharma & Biotech
Showing 1 of 1 calls · sorted by mentions
Choose a mentions count to open ticker posts.
u/justinrosser has 1 trade ideas tracked on Buzzberg across 1 tickers since September 2026. Most covered: IVVD.
Historical call returns are modeled from recorded ideas and stored prices, not actual brokerage portfolio returns. Check the evaluated call set and horizon; past results do not establish future prediction accuracy. Explore our data and methodology
